Live
- Kejriwal writes to HM Shah on law and order, seeks urgent meeting
- Big e-commerce firms to adopt Safety Pledge on National Consumer Day
- Cop ends life over torture by wife, father-in-law in Bengaluru
- Indian Constitution longest and most beautiful, Kiren Rijiju lauds its inclusive character
- BSNL's Rs 333 Plan Challenges Airtel and Jio with 1300GB Data: Details
- PM Modi's appeal to buy Khadi garments leads to huge demand in Bihar's Samastipur
- Mohammad Amir announces retirement from international cricket
- Chandrababu supports One Nation, One Election System, says elections in 2029
- Cong not pursuing politics of vengeance: D. K. Shivakumar on Covid 'scam' FIR
- Mexican consulates to strengthen support for nationals in face of US deportation
Diabetes drug may protect against Parkinson's
A new type of glitazone anti-diabetic may reduce the risk of developing Parkinson\'s disease, says a study. Diabetes patients on these drugs had a 28 per cent lower incidence of Parkinson\'s disease than people taking other anti-diabetics do.This is the first study to show the relationship between glitazone use and the incidence of Parkinson\'s disease in humans.
A new type of glitazone anti-diabetic may reduce the risk of developing Parkinson's disease, says a study. Diabetes patients on these drugs had a 28 per cent lower incidence of Parkinson's disease than people taking other anti-diabetics do.This is the first study to show the relationship between glitazone use and the incidence of Parkinson's disease in humans.
Researchers used electronic health records to match 44,597 glitazone users with 120,373 people using other anti-diabetic drugs. Glitazones activate the peroxisome proliferation-activated gamma (PPARI) receptor, which is found inside cells in many different body organs. PPARI activation by glitazones leads to reduced insulin resistance. However, the receptor has many other functions that have not been studied as thoroughly in humans.
.jpg)
"Our findings provide unique evidence that we hope will drive further investigation into potential drug treatments for Parkinson's disease. It's thought that around one in 500 people are affected by Parkinson's, and to date no effective treatments have been found to directly tackle the neurodegenerative aspect of the disease," said senior author Ian Douglas from the London School of Hygiene & Tropical Medicine.
The study outlined in PLOS Medicine looked at more than 160,000 diabetes patients. Patients were followed up from 1999 (when glitazones were introduced to treat diabetes) until 2013, to determine how many were diagnosed with Parkinson's disease during that period.
